Crohn's Disease Clinical Trial
Extra iron may not be necessary in the treatment of iron deficiency anemia in Crohn's Disease;Oxidative Stress and Inflammation may be Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia.
Anemia is one of the commonest extra-intestinal manifestations of Crohn's disease (CD) with
a prevalence ranging from 6.2% up to 73.7%.Compared with other complications,it has been
subestimated and received less attention from gastroenterologists, although,which is
frequently associated with a reduced quality of life.What's more,there were not appropriate
strategies for the adequate treatment of anaemia in CD either.
The anaemia in CD is caused by several factors, such as iron, folic acid or B12 deficiency,
treatment with immunosuppressive drugs or sulfasalazine-induced hemolysis, and anemia of
chronic disease, of which iron deficiency was one of the most important mechanisms.
Additionally, erythropoietin(EPO) levels in chronic disease anemia are generally higher than
in normal subjects.However, in CD anemic patients this EPO increase is inadequate in
relation to the degree of anemia.Thus, in the treatment of iron deficiency anemia (IDA) in
CD,EPO and iron supplementation are very common.Because intravenous(IV) iron is more
effective and better tolerated than oral iron and is to be considered in patients with
severe anemia (Hb＜10.0 g/dL), with intolerance or inadequate response to oral iron and/or
those with active IBD. Intravenous iron administration is the route of choice when
simultaneous treatment with erythropoiesis stimulat-ing agents (ESA) is considered.
But parenteral iron formulations have potential toxic effects such as triggering oxidative
reactions and inflammatory reactions that may be very disadvantageous to CD patients. Free
iron may provoke formation of free oxygen radicals. Although complex carbohydrate structures
that cover free iron may alleviate this oxidative and inflammatory potential,it cannot be
completely blocked. These suggest that parenteral iron could be a "double-edged sword" with
the hematologic benefits (increase in hemoglobin [Hb]) on the one hand, and with the risk of
enhancement of systemic inflammation and oxidative stress on the other.
Although the oxidative potential of intravenous iron (IVI) has been studied
extensively,there have been no studies about the effects of parenteral iron therapy on
oxidative stress and inflammatory markers in the CD population. In this study, we compared
different types and schedules of iron compounds for their effects on serum
inflammatory-oxidative stress indices.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03815851 -
Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery
|
N/A | |
| Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
| Completed |
NCT02883452 -
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
|
Phase 1 | |
| Recruiting |
NCT04777656 -
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
|
Phase 3 | |
| Terminated |
NCT03017014 -
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
|
||
| Recruiting |
NCT06053424 -
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
|
Phase 1 | |
| Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
| Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
| Terminated |
NCT02882841 -
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
|
N/A | |
| Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A | |
| Terminated |
NCT02417974 -
Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
|
Phase 2 | |
| Completed |
NCT03010787 -
A First Time in Human Study in Healthy Volunteers and Patients
|
Phase 1 | |
| Completed |
NCT02542917 -
Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
|
||
| Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
| Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
| Completed |
NCT02193048 -
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
|
||
| Completed |
NCT02265588 -
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).
|
N/A | |
| Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
| Recruiting |
NCT02395354 -
Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease
|
N/A | |
| Completed |
NCT01958827 -
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
|
Phase 3 |